STAT | Reporting from the frontiers of health and medicine Follow STAT+: Amylyx endocrine drug succeeds in pivotal study In a Phase 3 trial of people with post-bariatric hypoglycemia, those taking the drug, avexitide, experienced a 55% reduction in the rate of serious low blood sugar events compared with… https://www.statnews.com/2026/08/18/amylyx-endocrine-drug-succeeds-in-pivotal-study-avexitide-bariatric-surgery-patients/ statnews.com
